您当前的位置：

Izorlisib

(Synonyms: CH5132799)

目录号: PL09793 纯度: ≥98%

Izorlisib (CH5132799) 是一种选择性的 I 类 PI3K 抑制剂。抑制 PI3Kα, IC50 为 14 nM。

CAS No. :1007207-67-1

商品编号	规格	价格	会员价
PL09793-5mg	5mg	¥1075.00	请登录
PL09793-10mg	10mg	¥1725.00	请登录
PL09793-50mg	50mg	¥4565.00	请登录
PL09793-100mg	100mg	¥6385.00	请登录
PL09793-200mg	200mg	询价	询价
PL09793-500mg	500mg	¥12795.00	请登录
PL09793-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2958.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Izorlisib
中文别名	[5-[7-甲磺酰基-2-(吗啉-4-基)-6,7-二氢-5H-吡咯并[2,3-D]嘧啶-4-基]嘧啶-2-基]胺;CH5132799 抑制剂
英文名称	Izorlisib
英文别名	5-[7-(Methylsulfonyl)-2-(4-morpholinyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-pyrimidinamine;CH5132799;5-(7-(Methylsulfonyl)-2-morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine;5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine;5-(7-methanesulfonyl-2-morpholin-4-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrimidin-2-ylamine;cc-614;CH-5132799;CHEBI:1175318;CHEMBL1684984;QCR-47;SureCN2377154;5-(7-(Methylsulfonyl)-2-morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-ami;[5-[7-Methylsulfonyl-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-yl]amine;CH5132799,5-(7-(Methylsulfonyl)-2-Morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyriMidin-4-yl)pyriMidin-2-aMine;[5-[7-Methylsulfonyl-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrimidin-2-yl]amine CH5132799;CH 5132799;JCL936W835;C15H19N7O3S;(5-(7-Methylsulfonyl-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrimidin-2-yl)amine;JE;Izorlisib
Cas No.	1007207-67-1
分子式	C₁₅H₁₉N₇O₃S
分子量	377.42
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	Izorlisib (CH5132799) 是一种选择性的 I 类 PI3K 抑制剂。抑制 PI3Kα, IC50 为 14 nM。

产品详情

Izorlisib (CH5132799) 是一种选择性的 I 类 PI3K 抑制剂。抑制 PI3Kα, IC₅₀ 为 14 nM。

生物活性

Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC 50 of 14 nM.

性状

Solid

IC50 & Target[1][2]

PI3Kα 14 nM (IC50) PI3Kα-H1047R 5.6 nM (IC

体外研究(In Vitro)

Izorlisib (CH5132799) is a selective class I PI3K inhibitor with potent antitumor activity against tumors harboring the PIK3CA mutations. Izorlisib selectively inhibits class I PI3Ks and PI3Kα mutants in in vitro kinase assays. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM. IC50 values against class II PI3Ks (C2α and C2β), a class III PI3K (Vps34), and a class IV PI3K (mTOR) are more than 100-fold higher than that against PI3Kα. Interestingly, slightly lower IC50 values are observed against PI3Kα with oncogenic mutations E542K, E545K, and H1047R than against wild-type (WT) PI3Kα. In an analysis of cocrystal structure with PI3Kγ (PBD ID: 3APC), Izorlisib is shown to interact with ATP-binding sites of the enzyme, suggesting an ATP competitive mode of inhibition. No significant inhibitory activities of Izorlisib are

体内研究(In Vivo)

Mice bearing BT-474 tumors (n=14) are orally administered 50 mg/kg of Everolimus on a daily basis for 31 days and then randomized. After randomization, the mice are orally administered 50 mg/kg of Everolimus (n=4) and 12.5 mg/kg (n=5), and 25 mg/kg (n=5) of Izorlisib on a daily basis for 7 days. C, the vehicle-, Everolimus, and CH5132799-treated (25 mg/kg) tumors are resected at 4 hours after terminal administration in B, lysed, and analyzed by Western blotting. Izorlisib administration leads to a remarkable regression in a dose-dependent manner of the tumors regrown after the long-term Everolimus treatment. The tumors are resected at the end of treatment and analyzed by Western blotting with respect to PI3K pathway inhibition. Izorlisib suppresses various effectors in the PI3K pathway, including Akt, FoxO1, S6K, S6, and 4E-BP1, whereas Everolimus inhibits only phosphorylation

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Tanaka H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res, 2011, 17(10), 3272-3281.
[2]. Ohwada J, et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Leff, 2011, 21(6), 1767-1772.

溶解度数据	In Vitro: DMSO : 4.55 mg/mL (12.06 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Izorlisib

相关产品

The molarity calculator equation

The dilution calculator equation